
	Where results make sense

Topic: Shire Pharmaceuticals

Related Topics

Lundbeck

List of pharmaceutical companies

AstraZeneca

Pharmacia

Lists of companies

List of European companies

MAN (company)

Adderall

Wyeth

ALZA Corporation

Abbott Laboratories

List of Slovenian companies

Merck

Pierre Fabre Group

Cipla

In the News (Mon 16 Nov 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Commission Legal Brief: Gryl v. Shire Pharmaceuticals Group / June 21, 2002
		The plaintiffs allege that defendants acquired options in Shire Pharmaceuticals Group PLC ("Shire") while the defendants were directors of Shire and then exercised some of their options and sold the resultingShire stock within six months of acquiring the options.
		The plaintiffs further contend that the Shire Board's approval was deficient in that it did not state that it was for the purpose of exempting the transactions from Section 16(b).
		Most notably, the plaintiffs point to a Shire board resolution from six weeks before the merger became effective, which states that "conditional upon completion of the Merger and admission of the Consideration Shares to the Official List, [the defendants] are hereby appointed as non-executive directors of the Company" (A785).
	www.sec.gov /litigation/briefs/shire062102.htm (5343 words)

	medications - Shire Pharmaceuticals
		Founded in 1986, Shire Pharmaceuticals Group plc is a rapidly growing international emerging pharmaceutical company with revenues for the full year 2002 of $1,037.3 million and an operating income of $327.038 million.
		Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international emerging pharmaceutical company with a strategic focus on four therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI), oncology, and anti-infectives.
		Shire's core strategy is based on research and development combined with in-licensing and a focus on key pharmaceutical markets.
	www.shire-medications.co.uk (390 words)

	Shire Pharmaceuticals boosted by first Fosrenol approval
		Shire is a specialist pharmaceutical company that is focused on a small number of therapeutic areas.
		Shire believes that current therapies are not ideal: aluminum salts can cause bone and/or neural toxicity and are no longer widely used, and calcium salts are inefficient binders that require large doses and often cause hypercalcemia.
		Shire will determine what additional studies, if any, will be required, and whether these additional data will be required prior to approval or as part of post-marketing studies.
	www.bioportfolio.com /news/datamonitor_59.htm (772 words)

	Shire receives approvable letter from FDA for Fosrenol (R)
		Shire is initiating a dialogue with the FDA to agree the balance between pre and post approval commitments which will resolve the questions.
		Shire will give further updates when it is in a position to be more specific about the timing of approval and subsequent launch.
		Shire's core strategy is based on research and development combined with in-licensing and a focus on eight key pharmaceutical markets.
	www.eurekalert.org /pub_releases/2003-03/pn-sra030303.php (692 words)

	Shire US Inc Corporate Profile (Site not responding. Last check: 2007-10-31)
		Shire US Inc., a subsidiary of Shire Pharmaceuticals Group, is a fast-growing pharmaceutical company with more than 600 employees.
		Shire is best known in the United States for Adderall and Adderall XR, the leading brand for ADHD treatment and for which over 20 million prescriptions have been written.
		Founded in 1986, Shire Pharmaceuticals Group is a fast-growing, international specialty pharmaceutical company with a strategic focus on three therapeutic areas: CNS disorders, oncology and anti-infectives.
	www.gastroendonews.com /htmreader.cfm?artid=4938&file=protected/shireusinc.htm (652 words)

	New River Pharmaceuticals: Press Release
		Shire may be entitled to refunds of amounts previously paid in the event of a delayed product approval, or upon FDA approval depending on the characteristics of the approved product labeling.
		Shire's CNS expertise and leadership position in the ADHD market allows them to significantly contribute to this collaboration in a manner that we believe will optimally serve the interests of our shareholders.
		Shire Pharmaceuticals Group Plc is a global pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system, gastrointestinal and renal diseases.
	phx.corporate-ir.net /phoenix.zhtml?c=179878&p=irol-newsArticle&ID=668364&highlight= (1008 words)

	Shire
		Shire already has a wide range of products on the market and continues to use our search and development expertise to ensure that it can make more products available for these medically challenging diseases in the future.
		As a company, Shire has a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI), renal diseases and human genetic therapies.
		ZEFFIX is indicated for the treatment of chronic hepatitis B infection associated with evidence of hepatitis B viral replication and acute liver inflammation.
	www.shire.com /shire/Products/index.jsp?tn=4 (735 words)

	Shire Pharmaceuticals: Investing in a Promising Future (Site not responding. Last check: 2007-10-31)
		Shire's in-licensing and merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
		The '768 patent is directed to pharmaceutical compositions comprising a once-a-day sustained release formulation of at least one amphetamine salt for the treatment of ADHD.
		Shire and Janssen's affiliate, Johnson & Johnson Pharmaceutical Research & Development, LLC, are in ongoing discussions with the European regulatory authorities in relation to their assessment of the data for REMINYL from investigational studies in mild cognitive impairment.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-03-2005/0004207329&EDATE= (4003 words)

	Shire: Careers - Worldwide Careers Home
		Shire is a dynamic, growth company with operations worldwide.
		Shire enjoys the best of both worlds – a solid history of success built over the past two decades, yet with the feel and excitement of a high growth company building a successful business model in the pharmaceutical industry.
		We have a globally integrated, team-based organization structured to support our current and future requirements; however, we will maintain an environment that allows each employee to truly have a positive impact and make a difference in the success of the company.
	careers.shire.com (98 words)

	Shire Pharmaceuticals Group plc - Company Profile - Food Business Review
		For the fiscal year ended December 2004, Shire Pharmaceuticals Group (Shire) generated revenues of $1,363.2 million, an increase of 12.5% from the restated figures of the previous year.
		Shire had a net income of $269 million in fiscal 2004, down, 2.6% from the previous year.
		Shire reports its revenues as originating from four sources.
	www.food-business-review.com /companyprofile.asp?guid=39B0862A-AA0E-4B83-AE80-E70892133CE4&CType=Product (355 words)

	BostonWorks - Shire Pharmaceuticals, Inc. -- Cambridge Jobs and Employer Profile
		Shire's mission is to develop and market medicines that improve the quality of life for patients and their caregivers.
		Shire's research and development focus is on late stage, lower risk projects in areas where the company has commercial presence.
		Shire is also investigating the expansion of its ADHD expertise into countries outside the US - a currently small but potentially growing market as the recognition and diagnosis of the disease becomes more widespread.
	bostonworks.boston.com /research/profiles/tkt.shtml (758 words)

	BBC NEWS \| Business \| Shire confirms talks over patent
		Shire is currently suing Barr to stop it launching a generic version of its hyperactivity drug Adderall.
		Shire said it was considering all options relating to the legal action.
		Shire said on Friday that it had not ruled out settling its litigation or reaching an agreement with Barr Pharmaceuticals to allow the firm to market a cheaper version of Adderall in the US before 2018.
	news.bbc.co.uk /go/rss/-/1/hi/business/4164986.stm (282 words)

	Supernus Pharmaceuticals, Inc. : News and Events : Archived Shire Laboratories Press Releases (Site not responding. Last check: 2007-10-31)
		Shire Pharmaceuticals Group plc announces promising results from the reformulation of sampatrilat, a dual inhibitor of neutral endopeptidase and angiotension converting enzyme.
		Shire Laboratories Inc., a subsidiary of the Shire Pharmaceuticals Group plc (andquot;Shireandquot;) (LSE: SHP.L, NASDAQ: SHPGY), today announced that it signed four partnerships with different pharmaceutical companies in the year 2000.
		Shire Pharmaceuticals Group plc (LSE : SHP.L, Nasdaq : SHPGY) announces that a New Drug Application for SLI 381, the novel once-a-day formulation of Adderall for Attention Deficit Hyperactivity Disorder (ADHD) was delivered to the FDA yesterday.
	www.shirelabs.com /news/pr/shire_pr.html (1369 words)

	Shire Pharmaceuticals
		A global specialty pharmaceutical company with an exciting future of growth and opportunity, Shire enjoys the best of both worlds - a history of success combined with the atmosphere and energy of a dynamic company building a winning business model.
		Shire has grown faster than many other companies in the industry and is now one of the fastest growing specialty pharmaceutical companies in the world.
		Shire is driven by a passionate focus on people: specialist physicians, patients and our employees.
	www.biospace.com /company_profile.aspx?CompanyID=2688 (245 words)

	Shire US Inc Corporate Profile (Site not responding. Last check: 2007-10-31)
		Shire US, Inc., a subsidiary of the global company Shire Pharmaceuticals Group, is a fast-growing pharmaceutical company with more than 750 employees.
		Shire Pharmaceuticals Group is a fast-growing international pharmaceutical company.
		Shire’s year 2002 revenues were in excess of US $1 billion.
	www.gastroendonews.com /htmreader.cfm?artid=7878&file=content/shireusinc.htm (603 words)

	Shire Pharmaceuticals Group plc, Shire Acquisition Inc. and 3829359 Canada Inc. (Site not responding. Last check: 2007-10-31)
		Shire is currently subject to the applicable informational requirements in the United Kingdom and of the United States Securities Exchange Act of 1934, as amended, and is not a reporting issuer or the equivalent under the Legislation.
		The holders of shares of Shire and the holder of the Special Voting Shares will vote together as a single class on all matters, except as may be required by applicable law or the Shire articles of association.
		Shire will send concurrently to all holders of Shire Ordinary Shares or Shire ADSs resident in Canada all disclosure material furnished to holders of shares of Shire Ordinary Shares or Shire ADSs resident in the United States including, without limitation, copies of its annual financial statements and all proxy solicitation materials.
	www.msc.gov.mb.ca /orders/shire.html (3385 words)

	Shire Pharmaceuticals to Initiate Trial of AMPAKINE(R) CX516 in Patients with Attention Deficit Hyperactivity Disorder ...
		Shire Pharmaceuticals to Initiate Trial of AMPAKINE(R) CX516 in Patients with Attention Deficit Hyperactivity Disorder (ADHD) -- Phase II Study to Begin in July 2001
		Should Shire elect to execute this agreement, Cortex would receive an upfront fee, milestone payments based on successful clinical and commercial development, research support for additional AMPAKINE compounds, and royalties on sales.
		The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells.
	www.riskworld.com /PressRel/2001/01q2/PR01a056.htm (555 words)

	Shire Pharmaceuticals - Analyst News \| newratings.com (Site not responding. Last check: 2007-10-31)
		Shire Announces NDA Submission of Guanfacine Extended Release for the Treatment of ADHD in Children and Adolescents
		Shire Announces Filing of SPD465 for the Treatment of Adult ADHD
		Shire is Appealing Against the National Institute for Health and Clinical Excellence's Final Appraisal Determination on
	www.newratings.com /analyst_news/company_US82481R1068.html (278 words)

	Shire: Careers - Career Opportunities
		Shire is looking for outstanding, team-oriented individuals, who are motivated by the ability to make an immediate and sustained contribution in the workplace and have the opportunity to grow and develop professionally.
		We truly believe that our people make Shire successful, and we want to build and sustain Shire as a terrific place to work, grow and develop, and contribute to the world at large.
		Shire is an Equal Opportunity and Affirmative Action Employer.
	careers.shire.com /career_opportunities.asp (135 words)

	globeandmail.com : globeinvestor.com : BioChem Pharma Inc. - Corrected News Release - Superceeds Release On The Same ...
		Shire is an international specialty pharmaceutical company with a strategic focus on four therapeutic areas: central nervous system disorders, metabolic diseases, oncology and gastroenterology.
		BioChem Shareholders will be entitled to receive new Shire Shares or new Shire ADSs in exchange for their BioChem Shares, with an exchange ratio based on the average closing price of a Shire ADS during the last fifteen trading days ending on the third trading date prior to the Closing.
		On the basis of all facts and information disclosed by BioChem to Shire as at the date of the Merger Agreement, the outcome of the proceedings instituted by Emory University in the United States would not, for the purposes of the Agreement, be considered to have a material adverse change on BioChem.
	www.globeinvestor.com /servlet/WireFeedRedirect?slug=c3161&date=20001212&archive=cnw&cf=GlobeInvestor/config (5159 words)

	Shire Pharmaceuticals saw operating income double last year
		Shire Pharmaceuticals Group more than doubled its operating income in 2002 to $340 million, and a new acquisition of a transdermal patch to deliver one of its biggest products should help increase those results, the company said today.
		Shire, the British company that operates its U.S. headquarters in Newport, said it would pay up to $150 million for the worldwide sales and marketing rights to the Methypatch delivery system from Noven Pharmaceuticals Inc.
		Overall, Shire posted total revenue of $1.1 billion in 2002, including discontinued operations and up 21 percent compared to 2001.
	www.enquirer.com /midday/02/02282003_News_4mday_shirelate.html (235 words)

	List of pharmaceutical companies - Wikipedia, the free encyclopedia
		The following is a list of the top 50 pharmaceutical and biotech companies ranked by healthcare revenue.
		The phrase Big Pharma is often used to refer to companies with revenue in excess of $3 billion, and/or RandD expenditure in excess of $500 million, and represents the first 30 or so companies in this list.
		Knoll Pharmaceuticals, formerly the pharmaceutical division of BASF, acquired by Abbott in 2001
	en.wikipedia.org /wiki/List_of_pharmaceutical_companies (748 words)

	Noven and Shire Sign Development Agreement for New ADHD Patch
		Greg Flexter, Shire General Manager, North America, commented: "We are pleased that the methylphenidate transdermal system is proceeding under an agreed development plan.
		Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products.
		With the most advanced and broadly applicable transdermal technology in its class, Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders.
	www.noven.com /PR061604B.htm (482 words)

	Shire Pharmaceuticals seeks approval for Mesavance
		Shire Pharmaceuticals has filed a US new drug application (NDA) for its Mesavance treatment.
		The drug, which is designed to treat mild-to-moderate ulcerative colitis, is currently being studied for its effectiveness in inducing endoscopic and clinical remission in patients.
		Mesavance is the result of an agreement between Shire and Italian drug maker Giuliani, who has licensed Shire to develop and market the drug in the US, Canada, the Pacific Rim and the rest of Europe excluding Italy.
	www.allaboutmedicalsales.com /news/1205/Shire_Pharmaceuticals_Mesavance_23.html (266 words)

	shire - Shire Pharmaceuticals (Site not responding. Last check: 2007-10-31)
		We want to achieve this by researching, developing and marketing products of the highest quality for the prevention and treatment of serious diseases, which are treated by medical specialists.
		We already have a wide range of products on the market but are using our search and development expertise to ensure that we can make more products available for these medically challenging diseases in the future.
		As a company, Shire has a strategic focus on four therapeutic areas - central nervous system disorders, gastrointestinal, oncology and anti-infectives.
	www.shire-pharmaceuticals.com (331 words)

	BITC - Shire Pharmaceuticals Group plc (Site not responding. Last check: 2007-10-31)
		The most commonly reported initiative used by organisations to tackle turnover in the UK is to increase learning and development opportunities.
		Shire is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently has a range of projects and products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal.
		Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
	www.bitc.org.uk /directory/members/shire.html (166 words)

	Science & Medicine \| Shire Pharmaceuticals Licenses HIV Compound SPD754 to Australian Firm Avexa - Kaisernetwork.org
		U.K.-based Shire Pharmaceuticals Group on Monday announced that it has licensed its HIV compound SPD754 to Avexa, an Australian specialty anti-infectives company,
		SPD754, which is a non-nucleoside reverse transcriptase inhibitor, is currently in Phase II trials and is expected to reach the market in 2009.
		Shire officials said that this is one of the final steps in the group's divestment program, which is designed to focus efforts on later-stage investment in the areas of central nervous system, gastrointestinal and renal diseases,
	www.kaisernetwork.org /daily_reports/rep_index.cfm?DR_ID=27688 (267 words)

	PAPower: GOVERNOR RENDELL ANNOUNCES 400 NEW JOBS AT SHIRE PHARMACEUTICALS’ NEW U.S. HEADQUARTERS
		Shire Pharmaceuticals develops and markets specialty drugs for use in the treatment of central nervous system, gastrointestinal and renal diseases.
		Shire generates 70 percent of its more than $1 billion in annual revenue in the United States.
		Shire Pharmaceuticals expects to be in its new facility by September 2004.
	www.state.pa.us /papower/cwp/view.asp?A=11&Q=436985&papowerNav=\|31734\| (480 words)

Try your search on: Qwika (all wikis)